Selegiline for Health & Longevity

Evidence Review created on 08/03/2026 using AI4L / Opus 4.8

Also known as: L-Deprenyl, Deprenyl, Selegiline Hydrochloride, (R)-(–)-Deprenyl, Eldepryl, Zelapar, Emsam, Jumex

Motivation

Selegiline (also known as deprenyl) is a prescription medicine first developed in the 1960s. In the body it blocks an enzyme that breaks down dopamine, a brain-signaling chemical tied to movement, motivation, and pleasure. Because the brain’s dopamine supply falls with age, slowing this breakdown has long attracted interest as a way to keep the aging brain working well for longer.

The drug is approved to treat Parkinson’s disease and, as a skin patch, depression. Its longevity reputation, however, comes from a different place. Starting in the late 1980s, a Hungarian scientist reported that low doses lengthened the lives of aging rats, and later work in dogs pointed the same way. These striking animal findings, alongside conflicting later studies, turned selegiline into one of the most discussed drugs in the life-extension community, even though direct human lifespan data do not exist.

This review examines what is known about selegiline when viewed through a health-and-longevity lens: how it works, the benefits and risks reported across human and animal research, how it is dosed, how it interacts with other drugs and habits, and where the current evidence is strong, weak, or simply unresolved.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Selegiline

Grokipedia hosts a dedicated, encyclopedic article on selegiline covering its pharmacology, approved uses, metabolism to amphetamine derivatives, and longevity research. It is a useful, broadly sourced reference for orienting to the compound.

Examine

No dedicated Examine article exists for selegiline.

Selegiline is a prescription drug, and Examine.com does not typically cover prescription medications, focusing instead on supplements and dietary compounds.

ConsumerLab

No dedicated ConsumerLab article exists for selegiline.

Selegiline is a prescription drug, and ConsumerLab does not typically cover prescription medications, concentrating instead on the testing of supplements, foods, and consumer health products.

Systematic Reviews

A real-time PubMed search identified systematic reviews and meta-analyses evaluating selegiline; those most relevant to its efficacy, safety, and mortality signal are listed below.

Efficacy and Safety of Selegiline for the Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis - Wang et al., 2023

Pools randomized controlled trials (RCTs, studies that randomly assign participants to treatment or control) of selegiline in Parkinson’s disease, reporting improved motor scores and delayed disability with an acceptable safety profile. It is the most current disease-specific efficacy synthesis.
Efficacy and Safety of Selegiline Across Different Psychiatric Disorders: A Systematic Review and Meta-Analysis of Oral and Transdermal Formulations - Rossano et al., 2023

Evaluates oral and skin-patch selegiline across depression and other psychiatric conditions, supporting an antidepressant effect for the transdermal form. It is directly relevant to selegiline’s mood-related benefits.
Comparison of Selegiline and Levodopa Combination Therapy Versus Levodopa Monotherapy in the Treatment of Parkinson’s Disease: A Meta-Analysis - Jiang et al., 2020

Finds that adding selegiline to levodopa improves motor outcomes and reduces required levodopa dose relative to levodopa alone. It quantifies the drug’s dopamine-sparing, adjunctive value.
Effect of Selegiline on Mortality in Patients With Parkinson’s Disease: A Meta-Analysis - Olanow et al., 1998

Directly addresses the early safety alarm from the UK trial by pooling long-term mortality data and concluding selegiline does not significantly increase death rates. It is the key reference for the drug’s contested survival signal, of central interest from a longevity perspective.
The Selegiline Transdermal System in Major Depressive Disorder: A Systematic Review of Safety and Tolerability - Robinson & Amsterdam, 2008

Summarizes safety and tolerability of the selegiline patch in major depressive disorder (MDD, clinical depression), including the reduced dietary-tyramine risk at the 6 mg/24 h dose. It is the foundational safety review for the transdermal formulation.

Mechanism of Action

Selegiline’s actions fall into two conceptually distinct domains, and disentangling them is central to understanding its longevity claims.

Primary action - MAO-B inhibition. At low oral doses (up to about 10 mg/day), selegiline is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B, a brain enzyme that breaks down dopamine and other monoamines). By blocking MAO-B, it raises and stabilizes dopamine levels in the brain. Just as importantly for the aging argument, MAO-B activity itself rises with age, and each cycle of dopamine breakdown by MAO-B generates hydrogen peroxide (H₂O₂), a reactive by-product that contributes to oxidative stress on neurons. Reducing this flux is proposed to lower the oxidative burden on dopamine-producing cells.

Secondary action - the “enhancer” effect and neuroprotection. Joseph Knoll argued that at very low, sub-MAO-inhibitory concentrations, selegiline acts as a catecholaminergic activity enhancer (CAE, meaning it amplifies the firing of dopamine- and noradrenaline-releasing neurons) independent of enzyme inhibition. Selegiline and its metabolites are also reported to be anti-apoptotic (they interfere with programmed cell-death signaling, in part by acting on the enzyme GAPDH, a metabolic enzyme that can also help trigger programmed cell death) and to induce antioxidant enzymes such as superoxide dismutase (SOD, which neutralizes reactive oxygen molecules) and catalase in the brain and other tissues. This antioxidant-induction model, advanced chiefly by Kiyokazu Kitani, is the leading mechanistic explanation for the animal lifespan findings.

Competing interpretations. Not all researchers accept the CAE/enhancer concept; a competing view holds that selegiline’s benefits are fully explained by MAO-B inhibition and downstream dopamine and oxidative effects, and that the amphetamine-like metabolites (see below) account for some perceived stimulation. Both models remain debated.

Key pharmacological properties. Selegiline is highly selective for MAO-B over MAO-A (monoamine oxidase A, the related enzyme that preferentially breaks down serotonin and noradrenaline) at low doses, losing that selectivity as the dose climbs. Oral bioavailability is low and variable because of extensive first-pass metabolism; as a small, highly lipophilic molecule it is distributed widely into tissues and readily crosses the blood-brain barrier to reach its central targets. The parent drug’s half-life is short (roughly 1.5-3.5 hours), but because it binds MAO-B irreversibly, the biological effect persists until new enzyme is synthesized (on the order of two weeks). It is metabolized mainly by the liver enzyme CYP2B6 (a drug-metabolizing enzyme), with contributions from CYP2C19 and CYP3A4, yielding L-desmethylselegiline, L-methamphetamine, and L-amphetamine. The transdermal patch bypasses first-pass metabolism, producing higher parent-drug exposure with proportionally fewer amphetamine metabolites.

Historical Context & Evolution

Selegiline was synthesized in the early 1960s by Joseph Knoll and colleagues in Hungary, originally explored as a “psychic energizer” and antidepressant that, unlike earlier monoamine oxidase inhibitors, would not provoke the dangerous tyramine (“cheese”) reaction. Its MAO-B selectivity was characterized over the following decade, and it entered clinical use for Parkinson’s disease, where adding it to levodopa smoothed symptoms and appeared to delay disability.

The longevity story began in 1988, when Knoll reported that low-dose deprenyl more than doubled the remaining life expectancy of aging rats. The actual findings, rather than only their reception, are worth stating: subsequent groups saw increases in average lifespan (for example, roughly 15-34% in Fischer-344 rats in Kitani’s work) but generally not in maximum lifespan, while a widely cited beagle study by Milgram found longer survival and preserved cognition in older dogs. Other experiments — in certain mouse strains and in fruit flies — showed no benefit or even shortened survival, and a Fischer-344 study reported greater mortality in treated animals.

These results were never cleanly “debunked”; rather, they proved strain-, dose-, sex-, and age-dependent, which is why the picture remains genuinely mixed rather than settled in either direction. A parallel scare came from a large UK Parkinson’s trial in the 1990s that reported increased mortality with selegiline plus levodopa; later re-analysis and the pooled meta-analysis by Olanow and colleagues did not confirm a significant mortality increase, and methodological criticisms of the original trial were raised. The evolution of opinion has thus been non-linear: early enthusiasm, a safety scare, partial rehabilitation, and continued uncertainty, with the low-dose “prophylactic longevity” proposal remaining outside mainstream practice and never tested in a dedicated human longevity trial.

Expected Benefits

High 🟩 🟩 🟩

Protection of the Brain’s Dopamine System

Selegiline reliably preserves dopamine signaling and slows the progression of motor decline in Parkinson’s disease, the setting where its effect is best established. Meta-analyses of randomized controlled trials show it improves motor scores as monotherapy and, added to levodopa, reduces the required levodopa dose and delays disability. For a longevity-minded reader, the relevant implication is a demonstrated capacity to defend the specific neuronal population that erodes most visibly with age. The evidence basis is multiple RCTs and meta-analyses, though it derives from a diseased population rather than healthy agers.

Magnitude: In early Parkinson’s disease, selegiline delays the need to start levodopa by roughly 9 months on average and produces small but consistent improvements in motor rating scales versus placebo.

Medium 🟩 🟩

Mood Elevation and Antidepressant Effect

The transdermal patch (Emsam) is approved for major depressive disorder, and pooled analyses support a genuine antidepressant effect, while low-dose oral use is often reported to lift mood, motivation, and drive. The proposed mechanism combines raised dopamine with, at higher patch doses, added inhibition of MAO-A that boosts serotonin and noradrenaline. Evidence is strongest for the patch in clinical depression; the subtler “mood and motivation” benefit claimed by low-dose users rests on smaller studies and self-report. This benefit is directly relevant to healthspan, where drive and mood are core outcomes.

Magnitude: In depression trials the patch produces response and remission rates modestly above placebo (typically a 10-15 percentage-point advantage in responder rates).

Low 🟩

Antioxidant Defense and Neuroprotection ⚠️ Conflicted

In animals and cell models, selegiline induces protective antioxidant enzymes (such as superoxide dismutase and catalase) and blocks programmed cell death, which underpins the longevity hypothesis. The conflict is that these effects are robust in rodents and in vitro but have never been convincingly demonstrated to translate into measurable neuroprotection in healthy humans, and even in Parkinson’s disease whether the drug is truly “neuroprotective” versus merely symptomatic remains unresolved. The evidence basis is animal studies and mechanistic work, with human confirmation lacking.

Magnitude: Not quantified in available studies.

Cognitive Preservation in Aging ⚠️ Conflicted

Low-dose selegiline is promoted for maintaining memory, attention, and processing speed with age, supported by animal cognition data (including the Milgram dog studies) and small human trials. The conflict is stark: a Cochrane systematic review of selegiline for Alzheimer’s disease found insufficient evidence to recommend it, and results in healthy older adults are inconsistent. The honest reading is a plausible but unproven cognitive benefit, stronger in animals than in people.

Magnitude: Not quantified in available studies.

Speculative 🟨

Lifespan Extension

The headline longevity claim — that low-dose selegiline lengthens life — rests almost entirely on animal experiments that are themselves conflicting, with increases in some rat strains and dogs, no effect or harm in others, and no maximum-lifespan extension in most. No human study has ever tested selegiline for lifespan or all-cause mortality in a healthy population; the best human mortality data (in Parkinson’s disease) show neither a clear survival benefit nor, on balance, a clear harm. The basis for this item is therefore mechanistic and animal-anecdotal only.

Enhanced Libido and Sexual Vitality

Deprenyl has a longstanding reputation as a sexual enhancer, drawn largely from Knoll’s rat studies showing increased mating behavior in aged males and from user anecdote. Human controlled data are essentially absent, and any effect is presumed to flow from heightened dopamine and central arousal. This item is included because it is prominent in the longevity literature, but its basis is anecdotal and preclinical only.

Benefit-Modifying Factors

Genetic metabolism (CYP2B6, COMT): Variants in CYP2B6 (the main enzyme that clears selegiline) alter how much parent drug and amphetamine metabolite a person forms, shifting both stimulation and benefit. COMT (an enzyme that degrades dopamine) status may influence how much added benefit dopamine preservation yields.
Baseline dopamine tone: Individuals with lower baseline dopaminergic function — for reasons of age, genetics, or subclinical decline — are theoretically positioned to notice more benefit than those with an already robust dopamine system.
Sex-based differences: In animal longevity and behavioral studies, effects have frequently been larger or only present in males, and the reasons (hormonal, metabolic, dosing) are not fully understood; human sex-specific benefit data are lacking.
Pre-existing conditions: People with early Parkinsonian signs, depression, or age-related cognitive complaints have the most to gain, since these are the domains where selegiline’s effects are documented; healthy individuals may see little perceptible change.
Age: The mechanistic rationale strengthens with age because MAO-B activity rises and dopamine falls over time, so older members of the target range may in principle derive more mechanism-relevant benefit — though this remains a hypothesis, not a demonstrated age-graded effect.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Insomnia and Overstimulation

The most common practical problem, especially with oral dosing, is difficulty sleeping, jitteriness, or a “wired” feeling, driven by both raised dopamine and the L-amphetamine and L-methamphetamine metabolites the liver produces. It is dose-related and worse with later-in-day dosing. The effect is generally reversible on dose reduction or morning-only dosing, and it is a predictable consequence of the drug’s metabolism rather than an idiosyncratic reaction.

Magnitude: Insomnia is among the most frequently reported adverse effects, occurring in a substantial minority of users and rising with dose; exact rates vary by formulation and population.

Serotonin Syndrome with Serotonergic Drugs

Combining selegiline with serotonin-raising drugs can precipitate serotonin syndrome (a potentially life-threatening reaction of agitation, fever, rapid heart rate, muscle rigidity, and, at the extreme, death). Because selegiline is a monoamine oxidase inhibitor, this is a class-defining, boxed-warning-level hazard rather than a rare quirk, and it can occur even at low doses. It is largely preventable by avoiding the implicated drug combinations, but the consequences of failure are severe.

Magnitude: Rare when interacting drugs are avoided, but severe when it occurs; risk rises sharply with concurrent antidepressants, certain opioids, or other MAO inhibitors.

Medium 🟥 🟥

Orthostatic Hypotension and Dizziness

Selegiline can lower blood pressure on standing, producing orthostatic hypotension (a drop in blood pressure when rising that causes lightheadedness or faintness), particularly in older adults and with the transdermal patch. The mechanism relates to its effects on monoamine handling in the cardiovascular system. It is usually manageable with slow position changes and dose adjustment, but falls are a real concern in the older end of the target range.

Magnitude: Reported in a meaningful minority of patch users and older patients; typically mild-to-moderate and dose-dependent.

Nausea and Gastrointestinal Upset

Oral selegiline commonly causes nausea, and sometimes abdominal discomfort or dry mouth, often most noticeable when starting or increasing the dose. Taking it with food and titrating slowly generally mitigates it. This is a nuisance-level effect for most people rather than a dangerous one, and it tends to ease with continued use.

Magnitude: One of the more common oral side effects, affecting a notable fraction of users early in treatment; usually transient.

Hypertensive Reaction at High Doses (Tyramine)

At low, MAO-B-selective doses selegiline does not require dietary restriction, but as the dose rises and MAO-A is also inhibited, tyramine (an amino-acid by-product concentrated in aged cheeses, cured meats, and some fermented foods) can trigger a dangerous blood-pressure surge (hypertensive crisis). The transdermal patch carries specific dietary guidance above its lowest strength. This risk is essentially dose- and diet-dependent and avoidable by staying within selective dosing or observing restrictions.

Magnitude: Negligible at ≤10 mg/day oral or the 6 mg/24 h patch; clinically significant at higher doses without dietary care.

Low 🟥

Headache

Headache is reported across formulations and is usually mild and self-limiting, plausibly related to vascular and monoaminergic effects. It rarely requires discontinuation and often resolves as the body adjusts. It is included for completeness as a recognized, low-severity effect.

Magnitude: Common but mild; comparable to placebo rates in several trials.

Transdermal Application-Site Reactions

The patch can cause local redness, itching, or irritation where it is applied, which is generally mild and managed by rotating application sites. It is specific to the transdermal route and not a systemic concern. Dedicated dermatological-tolerability studies of the patch continue to be conducted.

Magnitude: Application-site reactions occur in a minority of patch users; most are mild and do not require stopping treatment.

Speculative 🟨

Long-Term Amphetamine-Metabolite Exposure

Because oral selegiline is metabolized to L-methamphetamine and L-amphetamine, chronic low-dose use raises a theoretical concern about cumulative stimulant exposure, effects on cardiovascular tone, or dependence-like patterns over years. There is little direct long-term human data at the low doses longevity users favor, and the L-isomers are less potent than their D-counterparts, so the concern is mechanistic and unquantified rather than demonstrated. The transdermal route largely sidesteps it by reducing metabolite formation.

Risk-Modifying Factors

Genetic metabolism (CYP2B6): Poor or rapid metabolizer status at CYP2B6 (the enzyme clearing selegiline) shifts how much amphetamine metabolite forms, modifying the likelihood of insomnia, overstimulation, and cardiovascular effects.
Baseline blood pressure: People with pre-existing hypertension or, conversely, a tendency to low standing blood pressure are more vulnerable to the drug’s pressor (high-dose tyramine) and hypotensive (orthostatic) extremes respectively, so baseline readings shape risk.
Sex-based differences: Sex differences observed in animal responses suggest possible differences in side-effect susceptibility, but human data are insufficient to define them; this is noted as an open factor rather than a quantified one.
Pre-existing conditions: Cardiovascular disease, bipolar disorder (risk of activation/mania), and any condition requiring serotonergic or certain opioid medications sharply raise the risk profile and can make the drug inadvisable.
Age: Older adults are more sensitive to orthostatic hypotension, sleep disruption, and drug-drug interactions due to polypharmacy, so the same dose carries greater risk at the older end of the target range.

Key Interactions & Contraindications

Serotonergic antidepressants (absolute contraindication): Selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline, paroxetine), serotonin-noradrenaline reuptake inhibitors (SNRIs, e.g., venlafaxine, duloxetine), and tricyclic antidepressants (TCAs, e.g., amitriptyline, clomipramine) must not be combined with selegiline — the consequence is serotonin syndrome. A washout period is required when switching (notably about 5 weeks after fluoxetine because of its long duration).
Other MAO inhibitors (absolute contraindication): Combining with other monoamine oxidase inhibitors (e.g., phenelzine, tranylcypromine, rasagiline, linezolid, methylene blue) risks additive hypertensive or serotonergic crisis.
Certain opioids (absolute contraindication): Meperidine (pethidine), tramadol, methadone, and dextromethorphan can provoke severe reactions including serotonin syndrome and must be avoided; consequence is life-threatening.
Sympathomimetics and stimulants (caution): Over-the-counter (OTC, non-prescription) decongestants (pseudoephedrine, phenylephrine), amphetamine stimulants, and some cough-cold products can raise blood pressure additively; monitor or avoid.
Supplement interactions (caution): Serotonergic or catecholaminergic supplements — St. John’s Wort, 5-HTP, L-tryptophan, tyrosine, and high-dose caffeine — can add to serotonin or stimulant load; St. John’s Wort in particular can contribute to serotonin syndrome.
Additive blood-pressure-lowering agents (monitor): Antihypertensives and other agents that lower standing blood pressure can compound selegiline’s orthostatic effect, increasing faint/fall risk; separate or monitor.
Populations who should avoid it: People with pheochromocytoma (an adrenaline-secreting tumor), those on any contraindicated drug above, individuals with uncontrolled hypertension or recent cardiovascular events, pregnant or breastfeeding individuals, and those with bipolar disorder at risk of manic activation.
Severity and mitigating actions: Where a combination is not absolutely contraindicated, mitigation includes dose separation, choosing the transdermal route to reduce metabolite load, blood-pressure monitoring, and observing the required washout intervals (e.g., at least 2 weeks off selegiline before starting a serotonergic drug, longer after fluoxetine).

Risk Mitigation Strategies

Low starting dose with slow titration: Begin at the lowest practical dose (commonly 5 mg oral in the morning, or 1.25-5 mg in low-dose longevity use) and increase gradually only if tolerated, which limits insomnia, nausea, and overstimulation from amphetamine metabolites.
Morning-only dosing: Take selegiline early in the day and avoid afternoon or evening doses to prevent the drug- and metabolite-driven insomnia and overstimulation.
Stay within MAO-B-selective dosing: Keep oral doses at or below 10 mg/day (or use the 6 mg/24 h patch) to preserve MAO-B selectivity and avoid the tyramine-related hypertensive crisis; observe patch dietary guidance at higher strengths.
Strict drug-interaction screening: Before starting, review every prescription, OTC, and supplement for serotonergic or sympathomimetic activity and honor washout periods (about 5 weeks after fluoxetine, 2 weeks in the other direction) to prevent serotonin syndrome and hypertensive events.
Prefer the transdermal route where metabolite exposure is a concern: Choosing the patch reduces first-pass conversion to L-methamphetamine and L-amphetamine, mitigating stimulant-type side effects and the speculative long-term metabolite concern.
Orthostatic precautions and blood-pressure monitoring: Rise slowly, maintain hydration, and check standing blood pressure periodically to catch orthostatic hypotension before it causes a fall, especially in older users.

Therapeutic Protocol

Standard clinical protocol (Parkinson’s disease): Leading practitioners use 5 mg orally at breakfast and, if needed, 5 mg at midday, for a total of 10 mg/day; the orally disintegrating form (Zelapar) is dosed at 1.25-2.5 mg once daily and is not equivalent milligram-for-milligram because it bypasses some first-pass metabolism.
Standard clinical protocol (depression): The transdermal system (Emsam) is applied once daily starting at 6 mg/24 h, titratable to 9 or 12 mg/24 h, with dietary tyramine precautions at the higher strengths.
Low-dose “longevity” approach: The main alternative, drawn from the life-extension community and Knoll’s prophylactic proposal, uses much lower doses — on the order of 1-5 mg/day, or 5 mg two to three times per week — on the theory that MAO-B inhibition and the enhancer effect are achievable well below symptomatic doses. This approach is not established by clinical trials and is presented here as a distinct school of practice, not a validated regimen.
Time of day: Morning dosing is preferred across approaches to avoid insomnia; the patch is typically applied at the same time each day.
Half-life and duration: The parent drug’s plasma half-life is short (about 1.5-3.5 hours), but because MAO-B inhibition is irreversible, the pharmacological effect outlasts the drug’s presence, persisting until new enzyme is made over roughly two weeks — which is why intermittent low-dose schedules are considered plausible.
Single versus split dosing: Oral daily totals up to 10 mg are commonly split into two morning-and-midday doses to limit peak side effects; low-dose longevity users often take a single small morning dose or intermittent doses.
Genetic considerations: CYP2B6 metabolizer status (and to a lesser extent CYP2C19) may justify starting lower in those predicted to form more amphetamine metabolite; COMT and APOE4 (a gene variant linked to Alzheimer’s risk) status are sometimes cited in longevity dosing discussions, though evidence for genotype-guided dosing is not established.
Sex-based and age considerations: Given larger effects in male animals and greater side-effect sensitivity in older adults, conservative starting doses are prudent for older users; robust human sex-specific dosing data are lacking.
Baseline biomarkers and pre-existing conditions: Baseline blood pressure (supine and standing) and a medication/supplement inventory should guide dosing, and pre-existing cardiovascular disease, bipolar disorder, or serotonergic medication use may contraindicate use entirely.

Discontinuation & Cycling

Lifelong versus short-term: In Parkinson’s disease and depression, selegiline is generally taken long-term for ongoing symptom control; in longevity use, proponents frame it as an indefinite low-dose prophylactic, though no evidence defines an optimal duration.
Withdrawal effects: Abrupt discontinuation after sustained use can occasionally produce a discontinuation reaction (including mood dip, fatigue, or, rarely, symptoms reminiscent of neuroleptic malignant syndrome (a rare but serious reaction marked by high fever, muscle rigidity, and confusion) reported with sudden withdrawal of antiparkinsonian drugs); most low-dose users report little on stopping.
Tapering: Because MAO-B inhibition wanes only as new enzyme is synthesized over about two weeks, the drug effectively self-tapers pharmacologically, but a deliberate dose reduction is still sensible after prolonged or higher-dose use rather than an abrupt stop.
Cycling: Some low-dose users cycle selegiline (e.g., several days on, then off, or several weeks on and off) on the rationale that irreversible enzyme inhibition persists between doses; this is a community practice without controlled evidence of added benefit or necessity.
Practical note: Any change should account for interacting drugs — the same washout logic applies when stopping selegiline before starting a serotonergic medication (allow about two weeks).

Sourcing and Quality

Prescription status and legitimate supply: Selegiline is a prescription medication; the highest-quality, correctly dosed product comes from a licensed pharmacy dispensing approved formulations (Eldepryl/generic capsules and tablets, Zelapar orally disintegrating tablets, Emsam patches).
Compounding pharmacies: For non-standard low doses used in longevity practice, a reputable compounding pharmacy can prepare precise strengths; verify accreditation (e.g., PCAB accreditation in the US) and request certificates of analysis.
Gray-market and “research chemical” caution: Deprenyl is widely sold online as liquid drops or capsules from overseas or research-chemical vendors; these bypass pharmacy quality control, and purity, actual content, and sterility cannot be assumed — a significant concern for a drug with a narrow safe-dosing window and serious interactions.
What to look for: Prefer products with verifiable manufacturer identity, lot numbers, and third-party or certificate-of-analysis testing confirming identity and purity, and confirm the isomer is the intended L-(R)-form rather than a racemic mixture.

Practical Considerations

Time to effect: Mood and alertness changes may be noticed within days to a couple of weeks; any putative neuroprotective or longevity effects, if real, would accrue over months to years and are not directly perceptible.
Common pitfalls: The most frequent mistakes are dosing too high or too late in the day (causing insomnia), overlooking a serotonergic or sympathomimetic drug/supplement interaction, and assuming the low-dose longevity regimen is evidence-based when it is not.
Regulatory status: Selegiline is approved by the U.S. Food and Drug Administration (FDA) for Parkinson’s disease (oral, Zelapar) and major depressive disorder (Emsam patch); use for longevity or general cognitive enhancement is off-label and not sanctioned by regulators.
Cost and accessibility: Generic oral selegiline is inexpensive and widely available; the Emsam patch and Zelapar are considerably more costly, and obtaining the drug for longevity use requires a willing prescriber, which can be a practical barrier.
Formulation choice: The oral route is cheapest and most flexible for low-dose use but produces amphetamine metabolites; the patch is pricier but reduces those metabolites and MAO-A dietary risk at its lowest strength.

Interaction with Foundational Habits

Sleep: The interaction is direct and generally negative if mistimed — dopaminergic and amphetamine-metabolite stimulation can cause insomnia, so dosing is kept to the morning; conversely, better daytime mood and energy may indirectly support sleep pressure. Avoid afternoon/evening dosing.
Nutrition: The interaction is direct and dose-dependent: at low, MAO-B-selective doses no dietary restriction is needed, but at higher doses or higher patch strengths, tyramine-rich foods (aged cheese, cured/fermented meats, some fermented soy and draft beer) must be limited to prevent a blood-pressure surge. Taking oral doses with food reduces nausea.
Exercise: The interaction is largely indirect and potentiating for motivation and drive; there is no strong evidence it blunts training adaptations. Because both intense exercise and selegiline can affect blood pressure and heart rate, users prone to orthostatic symptoms should be attentive around workouts and stay hydrated.
Stress management: The interaction is indirect: by raising dopamine and, at higher doses, other monoamines, selegiline may improve stress resilience and mood, but overstimulation can heighten anxiety or agitation in susceptible people. Pairing with practices that lower sympathetic tone (breathing, adequate sleep) is sensible, and stimulant-like agitation is a signal to reduce dose.

Monitoring Protocol & Defining Success

Baseline assessment before starting selegiline should establish cardiovascular and mood status and a complete drug/supplement inventory, since the drug’s main hazards are interaction- and blood-pressure-related rather than organ-toxicity-related. The following labs and observations are the practical core.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Blood pressure (supine & standing)	~110-125 / 70-80 mmHg, with <20 mmHg systolic drop on standing	Detects orthostatic hypotension and any pressor response	Measure lying then standing; recheck after dose changes; a large standing drop signals fall risk
Resting heart rate	~55-70 bpm	Screens for stimulant-type cardiovascular effect from amphetamine metabolites	Best measured at rest, same time of day; rising trend warrants dose review
ALT and AST	ALT <25 U/L (men) / <20 U/L (women); AST ~15-25 U/L	Confirms healthy hepatic function for a liver-metabolized drug	ALT and AST are liver enzymes; conventional labs flag only >40 U/L as abnormal, higher than the optimal functional range; fasting not required
Vitamin B6 (pyridoxal-5-phosphate)	~30-80 nmol/L	MAO-inhibitor use can affect B6-dependent pathways; relevant with long-term use	Best paired with a general metabolic panel; not a routine requirement but reasonable for chronic users

Ongoing monitoring cadence: check blood pressure and heart rate at about 1-2 weeks after starting or dose change, again at 4-6 weeks, then every 6-12 months once stable; liver enzymes and B6 can be reviewed annually for long-term users.

Qualitative markers of success and tolerability to track:

Sleep quality and time to fall asleep (worsening flags mistimed or excessive dosing)
Energy, motivation, and mood through the day
Cognitive clarity, focus, and processing speed
Absence of jitteriness, palpitations, or lightheadedness on standing

Emerging Research

New transdermal formulations: A phase 1 study is evaluating skin irritation and sensitization of a new generic selegiline transdermal system against the reference patch (NCT07452692, 230 healthy subjects, sponsor Corium Innovations), reflecting continued industry interest in the patch route that minimizes amphetamine metabolites — the route most relevant to safer long-term use.
Oncology repurposing: A phase 2 trial is investigating selegiline combined with docetaxel in metastatic castration-resistant prostate cancer (NCT04586543, planned 110 participants), probing MAO-related pathways in cancer biology; its registry status is listed as unknown, but it illustrates a novel direction beyond neurology and psychiatry.
Antioxidant/longevity mechanism (could strengthen the case): Kitani and colleagues’ body of work proposing that deprenyl extends animal survival by inducing brain antioxidant enzymes remains the strongest mechanistic support and points to biomarker-based human studies as the next step (Kitani et al., 2002).
Low-dose combination longevity work (could strengthen the case): Later Knoll-lineage research on very low doses of selegiline and the related compound BPAP reported survival effects in rodents, keeping the low-dose “enhancer” hypothesis alive for future human testing (Knoll & Miklya, 2016).
Mortality re-analysis (could weaken the case): The pooled Parkinson’s mortality analysis that failed to show a survival benefit tempers longevity expectations and argues that any human lifespan effect, if present, is small — a direction future long-term human studies would need to resolve (Olanow et al., 1998).
Key open question: No dedicated human trial has ever tested low-dose selegiline for healthy-lifespan or all-cause mortality endpoints; such a study is the single most important piece of missing evidence and would most directly change current understanding.

Conclusion

Selegiline is a decades-old prescription drug that blocks a brain enzyme controlling dopamine, and at low doses it may also gently stimulate the neurons that use dopamine and related chemicals. Its everyday, well-supported value lies in protecting the brain’s dopamine system in Parkinson’s disease and, as a skin patch, in easing depression — both meaningful to anyone focused on keeping the brain and mood robust with age. Its fame in longevity circles, however, rests on animal experiments that lengthened the lives of some aging rats and dogs but not others, alongside laboratory findings that the drug boosts the body’s own antioxidant defenses. None of this has been tested for lifespan in people, and the one large human safety scare over survival was not confirmed on closer analysis.

The result is an intervention with solid evidence for specific brain and mood benefits, a real but manageable safety profile centered on drug interactions and overstimulation, and a longevity promise that remains genuinely unproven rather than disproven. Anyone weighing it is looking at strong mechanism and animal signals set against an absence of direct human longevity data, which leaves its longevity promise genuinely open rather than settled in either direction.

Top - Benefits - Risks - Protocol

Selegiline for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Protection of the Brain’s Dopamine System

Medium 🟩 🟩

Mood Elevation and Antidepressant Effect

Low 🟩

Antioxidant Defense and Neuroprotection ⚠️ Conflicted

Cognitive Preservation in Aging ⚠️ Conflicted

Speculative 🟨

Lifespan Extension

Enhanced Libido and Sexual Vitality

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Insomnia and Overstimulation

Serotonin Syndrome with Serotonergic Drugs

Medium 🟥 🟥

Orthostatic Hypotension and Dizziness

Nausea and Gastrointestinal Upset

Hypertensive Reaction at High Doses (Tyramine)

Low 🟥

Headache

Transdermal Application-Site Reactions

Speculative 🟨

Long-Term Amphetamine-Metabolite Exposure

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion